Literature DB >> 20972735

Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma.

Li-Qun Gu1, Feng-Ying Li, Lin Zhao, Yun Liu, Qian Chu, Xun-Xiong Zang, Jian-Min Liu, Guang Ning, Yong-Ju Zhao.   

Abstract

The expression of X-linked inhibitor of apoptosis (XIAP) and the P2X7 receptor were demonstrated in a variety of tumors. The purpose of the present study was to investigate the associations of XIAP and P2X7 receptor expression with the clinicopathological features of patients with papillary thyroid carcinoma (PTC). In this cross-sectional study, a total of 62 cases were examined, including 43 patients with PTCs and 19 with benign nodular goiters. XIAP and P2X7 receptor expression were examined by immunohistochemical methods on formalin-fixed, paraffin-embedded thyroid tissues. The staining intensity and extent were evaluated and scored using a semi-quantitative method. The immunohistochemical staining score integrating the intensity and extent of XIAP and P2X7 receptors in PTCs was higher than in nodular goiters. XIAP (OR: 5.6, 95% CI: 1.5-21.1, P=0.009) and P2X7 receptor (OR: 6.1, 95% CI: 1.5-24.4, P=0.007) expression were associated with lymph node metastasis in PTCs. In logistic regression analysis, P2X7 receptor expression, tumor size, and capsular infiltration were predictors for lymph node metastasis (P=0.001). Our results suggested that XIAP and P2X7 receptor expression may predict the aggressiveness of PTC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972735     DOI: 10.1007/s12020-010-9384-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  39 in total

Review 1.  Pathophysiology and therapeutic potential of purinergic signaling.

Authors:  Geoffrey Burnstock
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

2.  Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-11       Impact factor: 3.352

3.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

4.  Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma.

Authors:  S S Liu; B K Tsang; A N Cheung; W C Xue; D K Cheng; T Y Ng; L C Wong; H Y Ngan
Journal:  Eur J Cancer       Date:  2001-06       Impact factor: 9.162

5.  Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.

Authors:  Yue Wang; Xiu Long Niu; Ye Qu; Jian Wu; Ya Qin Zhu; Wei Jia Sun; Ling Zhi Li
Journal:  Cancer Lett       Date:  2010-03-16       Impact factor: 8.679

6.  The expression of monocyte chemotactic protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence.

Authors:  Katsuhiro Tanaka; Junichi Kurebayashi; Mai Sohda; Tsunehisa Nomura; Uma Prabhakar; Li Yan; Hiroshi Sonoo
Journal:  Thyroid       Date:  2009-01       Impact factor: 6.568

7.  P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin.

Authors:  Xin Li; Xiaoping Qi; Lingyin Zhou; Wen Fu; Fadi W Abdul-Karim; Gregory Maclennan; George I Gorodeski
Journal:  Purinergic Signal       Date:  2009-04-28       Impact factor: 3.765

8.  Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor.

Authors:  R M Ruggeri; D Villari; A Simone; R Scarfi; M Attard; F Orlandi; G Barresi; F Trimarchi; M Trovato; S Benvenga
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 9.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

10.  Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease?

Authors:  Anna Solini; Sabina Cuccato; Davide Ferrari; Eleonora Santini; Sara Gulinelli; Maria Giulia Callegari; Angela Dardano; Pinuccia Faviana; Stephanie Madec; Francesco Di Virgilio; Fabio Monzani
Journal:  Endocrinology       Date:  2007-10-18       Impact factor: 4.736

View more
  15 in total

1.  Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population.

Authors:  Ji Hye Yim; Won Gu Kim; Min Ji Jeon; Ji Min Han; Tae Yong Kim; Jong Ho Yoon; Suck Joon Hong; Dong Eun Song; Gyungyub Gong; Young Kee Shong; Won Bae Kim
Journal:  Thyroid       Date:  2013-12-13       Impact factor: 6.568

Review 2.  The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond.

Authors:  Cristina Conforti-Andreoni; Paola Ricciardi-Castagnoli; Alessandra Mortellaro
Journal:  Cell Mol Immunol       Date:  2011-01-24       Impact factor: 11.530

Review 3.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

4.  The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma.

Authors:  F Amoroso; M Capece; A Rotondo; D Cangelosi; M Ferracin; A Franceschini; L Raffaghello; V Pistoia; L Varesio; E Adinolfi
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

Review 5.  Research Progress in the Relationship Between P2X7R and Cervical Cancer.

Authors:  Yiqing Tang; Cuicui Qiao; Qianqian Li; Xiaodi Zhu; Ronglan Zhao; Xiaoxiang Peng
Journal:  Reprod Sci       Date:  2022-07-07       Impact factor: 3.060

Review 6.  Purinergic signaling in thyroid disease.

Authors:  Ying Le; Donghui Lu; Meng Xue
Journal:  Purinergic Signal       Date:  2022-03-26       Impact factor: 3.765

Review 7.  Mechanosensitive Ion Channels: TRPV4 and P2X7 in Disseminating Cancer Cells.

Authors:  Jacob M Hope; Joshua D Greenlee; Michael R King
Journal:  Cancer J       Date:  2018 Mar/Apr       Impact factor: 3.360

Review 8.  Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy.

Authors:  Wen-Jun Zhang
Journal:  Purinergic Signal       Date:  2021-01-09       Impact factor: 3.765

9.  Expression of X-linked inhibitor of apoptosis protein in neoplastic thyroid disorder.

Authors:  Ji Hye Yim; Jong Ho Yoon; Sun A Kim; Won Gu Kim; Min Ji Jeon; Ji Min Han; Tae Yon Sung; Tae Yong Kim; Won Bae Kim; Suck Joon Hong; Young Kee Shong; Gyungyub Gong
Journal:  J Korean Med Sci       Date:  2011-09-01       Impact factor: 2.153

10.  Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer.

Authors:  S Hector; S Conlon; J Schmid; P Dicker; R J Cummins; C G Concannon; P G Johnston; E W Kay; J H M Prehn
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.